Overcoming clinical inertia around starting and intensifying antihypertensive drugs is key, a researcher says.
Renal denervation, also known as the Symplicity™ blood pressure procedure, targets overactive nerves around the renal arteries that contribute to high blood pressure ...
Obesity is a chronic relapsing condition, and treatment options need to reflect this reality, write Sam West, Dimitrios A Koutoukidis, and Susan A Jebb The use of glucagon-like peptide-1 (GLP-1) ...
Overall, 44.7% of the ARB initiators were continuously persistent to their original drug class at 3 years. HealthDay News — For patients with hypertension, initiating treatment with an angiotensin ...
Quitting an energy drink habit helped a man lower his blood pressure when medicine could not. He was drinking eight energy drinks a day, far exceeding the recommended caffeine limit. After quitting ...
Please provide your email address to receive an email when new articles are posted on . Lifetime risk for hypertension is up to 90% among U.S. adults. Updated guidelines and a pipeline of novel drugs ...
The global anti-hypertensive drugs market size was calculated at USD 24.92 billion in 2024 and is expected to grow steadily from USD 25.94 billion in 2025 to reach nearly USD 37.24 billion by 2034, ...
Blood pressure medication was recalled by the FDA. The prescription drug didn’t meet the agency’s standards for a lack of carcinogenic potency. Over 580,000 bottles were recalled. No one wants to ...
No one wants to trade high blood pressure for a potentially cancer-causing chemical, which is why a blood pressure medication made by Teva Pharmaceuticals out of New Jersey was recalled by the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results